Abstract Thioridazine toxicity has been described as a 'progressive chorioretinopathy', but this designation can The latter terminology implies that thioridazine toxicity progresses after the drug has been stopped, as has been reported occasionally with chloroquine toxicity.8-" However, clinical experience with thioridazine is not altogether consistent with this description. For example, functional recovery within the first several months after stopping the drug has been noted repeatedly.4 121 3 It is critical to make distinctions between short and long term changes, between the evolution of pigmentation and the evolution of functional loss, and between pharmacological toxicity (from retained toxin) and the time related decompensation of subclinically injured tissue.
but recent articles have attached new significance to the findings: the late appearance has been termed a 'nummular retinopathy',6 and the evolution of pigmentation called 'progressive chorioretinopathy'. 7 The latter terminology implies that thioridazine toxicity progresses after the drug has been stopped, as has been reported occasionally with chloroquine toxicity.8-" However, clinical experience with thioridazine is not altogether consistent with this description. For 4), the prognosis over the long term is probably fairly good; in patients in whom there is more widespread damage in the early years (such as cases 1, 3, and 7) the prognosis will be much more guarded, since decompensation of the compromised RPE could eventually lead to diffuse atrophy.
Until the late pigmentary and functional changes in thioridazine can be clearly shown to be a result ofcontinued drug action I suggest that thioridazine toxicity not be referred to as a progressive chorioretinopathy. That 
